



# Workshop: Best Practice for Sex Inclusive Research

Natasha Karp<sup>1</sup>, Benjamin Phillips<sup>1</sup> and  
Amrita Ahluwalia<sup>2</sup>

1: Quantitative Biology, Discovery Science, R&D, AstraZeneca,  
UK.

2: Queen Mary University of London, UK.



# Outline

1

Terminology

2

Clinically sex matters

3

What is happening in preclinical research?

4

What is sex inclusive research?

5

Factorial analysis is critical element

6

Considering the barriers


7

Conclusion



1

# Terminology



# Gender / Sex – does terminology matter?

## Sex refers to

- *“the different biological and physiological characteristics of males and females, such as reproductive organs, chromosomes, hormones, etc”* World Health Organisation


## Gender refers to

- *“the socially constructed characteristics of women and men – such as norms, roles and relationships of and between groups of women and men. It varies from society to society and can be changed.”* World Health Organisation




2

Clinically does sex  
matters?






# Sex matters clinically




Prevalence



Symptoms



Progression



Side Effects


## COVID-19 [Bwire 2020; Doerre & Doblhammer 2022]

- Prevalence higher in ♀ but higher morbidity and mortality in ♂
  - Biological differences ?
    - Higher expression ACE 2 receptor for coronavirus in ♂
    - Immunological differences driven by sex hormone and X chromosome
- Gender differences
  - ♀ - more contacts, work in care roles
  - ♂ higher rates of smoking and drinking
  - ♂ Lower uptake of preventative measures




3

What is happening in  
preclinical research?



# Classic design - driven by minimising N






# Embedded neglect of sex within preclinical research

- Reporting:
  - In vivo: Sex not specified – 22% did not specify Yoon et al 2014
  - In vitro: 75% did not report the sex Shah 2014
- Experimental design:
  - In vivo: comparison across 9 fields of biology, 2009 to 2019 Beery 2020
    - 6/9 significant improvement, 1(Pharmacology) reduction to 29%, average 26% to 48%
  - In vitro: 69 -80% male only Taylor 2011, Shah 2014
- Analysis (In vivo):
  - When both sexes (N=356), only 42% sex-based analysis Beery 2020
  - Those reporting sex differences: 1/3 did not test statistically
  -



# Emerging evidence that our knowledge base is biased


27.6% female only



72.4% male only

Pain processing

N=127




Mogil (2020) Nature Reviews Neuroscience

Figure courtesy of Prof Jeffery Mogil (McGill University Canada) 2022



# Evidence: sex matters in early research



## ARTICLE

Received 27 Oct 2016 | Accepted 30 Mar 2017 | Published 26 Jun 2017


DOI: 10.1038/ncomms15475

OPEN

## Prevalence of sexual dimorphism in mammalian phenotypic traits

Natasha A. Karp<sup>1,2</sup>, Jeremy Mason<sup>3</sup>, Arthur L. Beaudet<sup>4</sup>, Yoav Benjamini<sup>5</sup>, Lynette Bower<sup>6</sup>, Robert E. Braun<sup>7</sup>,

7M + 7F Mutant Adult Mice




- 10 institutes
- 14,250 wildtype mice
- 40,192 mutant mice
- 2186 mutant lines
- up to 234 traits.




# SABV?

In control data




Categorical  
N=545




Continuous  
N=903

As a modifier of treatment effect?



Categorical

No ds = 266,952  
No ds sig = 1,220



Continuous

No ds = 110,586  
No ds sig = 7,929



# Sociological exploration of the issue

- Interviews to probe scientists' (n=9) thoughts and experiences

## **Generalizability**

- Important to embrace variation to understand biological differences

## **Avoiding complexity**

- To make progress in science reduce complexity

## **Practicality**

- Mediate tension between generalizability and avoiding complexity
- Convert the original research question into a doable problem
- Pragmatic constraints of which variables can be considered
- Availability of materials and cost constrained ability to include SABV






# MRC survey

- Majority of MRC researchers (95% of *in vivo* researchers and 88% of cell users) saw benefit of considering diversity
  - Translatability
  - Reproducibility
  - Detecting sex specific effects
- Barriers/Concerns
  - Cost of experiments and complexity of research design
  - Compliance with the principles of the 3Rs (animal usage for *in vivo* researchers)
  - Commercial availability of samples (cell researchers)



4

What is sex inclusive research?



# Sex and Gender Equity in Research (SAGER) guidelines

- Principles
  - Use the term sex and gender carefully
  - Where the subjects of research comprise organisms capable of differentiation by sex, the research should be designed and conducted in a way that can reveal sex-related differences in the results, even if these were not initially expected.
  - Where subjects can also be differentiated by gender (shaped by social and cultural circumstances), the research should be conducted similarly at this additional level of distinction

Heidari 2016 Research Integrity and Peer Review



# Funding bodies are driving change

- Movement from recommendation to requirement and active questions in funding process

Body	Year
NIH	2016 – required incorporation both <i>in vivo</i> and <i>in vitro</i>
Canadian Institute of Health Research	2010 – questions in grant application
Irish Research Council	2013 – questions in grant application
European Commission	2020 – required incorporation both <i>in vivo</i> and <i>in vitro</i>
MRC	2022 – inclusion of both sexes the default for <i>in vivo</i> and <i>in vitro</i>
CRUK	2023 – inclusion of both sexes the default for animal, tissues or cells

- WT funding - MESSAGE (Medical Science Sex and Gender Equity) project
  - Co-develop a sex and gender policy framework for funders and regulators in the UK



# Inclusion is the default – exclusion by exception

## Requirement

- Specify the sex for human or animal tissues and cells used in experiments
- Inclusion of both sexes as default for studies involving animals and human and animal tissues and cells
- Analysis should account for sex

## Vision

- Experiments are powered to detect the effect of interest across the two sexes
- Research will then estimate a **generalisable** result
- If the effect is very different between the sexes then this will become apparent






# Exception?

- Where sex cannot be determined
- Pure molecular studies such as P-P interactions
- Sex-specific conditions or phenomena e.g. ovarian cancer
- Acutely scarce resources (e.g. rare disease)
- If you can provide strong justification.





5

Factorial analysis is  
the critical element




# Statistics as understanding sources of variation

- Some of this variation is background/impractical to explain. Some of it is planned (e.g., treatments) and systematic.
- We often aim to explain variability in the data through predictors that we control or observe:



# Common sources of variation



# Managing sources of variation

## Known sources:

- Control (i.e. standardise)
- Block
- Factor of interest

## Unknown sources:

- Randomize






# Statistical strategies- t-test vs block vs factor

## T-test


Simplest approach:  
compare two conditions



$Y \sim \text{environment}$

## Block


When the interaction is not  
of biological interest:



$Y \sim \text{treatment} + \text{environment}$

## Factor


When the differential  
effect is biologically  
interesting:




$Y \sim \text{treatment} + \text{genotype}$   
 $+ \text{treatment:genotype}$



# Moving from complete randomised to factorial design




$Y \sim \text{treatment}$




$Y \sim \text{treatment} + \text{sex} + \text{treatment} * \text{sex}$




# Testing the main effects: treatment and sex




# Testing the interaction: comparison of differences



# Some examples



Effect	Significant
Sex	X
Drug	✓
Interaction	X



Effect	Significant
Sex	✓
Drug	✓
Interaction	X



Effect	Significant
Sex	✓
Drug	✓
Interaction	✓





# Misconception: It will increase my animal usage

“Keep doing what you are already doing but change half the animals in your study to female”

*McCarthy 2015 Schizophrenia Bulletin*

- Evidence:
- Including both sexes in *in vivo* research does not necessitate an increase in sample size: a key role for factorial analysis methods (Phillips PLoS Biology 2023)
- Inclusion of females does not increase variability in rodent research studies (Beery Curr Opin Behav Science 2018)



# The interaction term is critical

“We will test the females once we understand the biology”


- Can't tell if the effect size is significantly different
- You never get to the second sex
- It is a structurally biased research approach
- “false assumption that what is discovered in males is how the brain really works, whereas in females, the same neurobiological processes are probably more complicated. ”
- “When females are studied through a male lens, the true crux of the research question for females can be missed. ”
- ARE HORMONES A “FEMALE PROBLEM” FOR ANIMAL RESEARCH?
- <https://www.science.org/doi/10.1126/science.aaw7570>




# Common mistakes & how to avoid them – misidentification of design (1)

It can be easy to misidentify the study design and use the wrong analysis as a result. These mistakes are common when researchers report studies involving both sexes:

## Pooling



## Disaggregation




# Common mistakes & how to avoid them- misidentification of design (2)

Another commonly seen error- treating a factorial design as a parallel group design and using a one-way ANOVA: Genotype \* Treatment design:


## Mistake:

- Fails to identify experimental structure- loss of power & fails to test the biology of interest:




## Correct:

- Enables estimation of interaction and main effects:



# A simulation-based approach for exploring factorial power


- 1) **Generate simulated data**
- 2) **Apply statistical test and extract p values**
- 3) **Repeat process 1000 times for each effect size of interest and calculate the % of significant p values as the statistical power for that scenario.**



## Scenarios


1. Baseline effect of sex
2. A differential effect of sex on treatment in the same direction
3. An effect in one sex only
4. Opposite effects of sex by treatment

# 1: When there is a baseline effect of sex?









## 2: When there is a differential effect in the same direction?



# Pooling compromises treatment power when there is an effect in one sex



# Power is passed to the interaction term when the effects are in opposite directions



# Simulation conclusions:

A factorial approach provides power benefits, compared to a pooling t-test approach.

Disaggregation of data by sex loses statistical power and doesn't test for the interaction.

Typically, there is no loss of power to detect a treatment effect when including both sexes.

When power is lost, the knowledge gained is vital as the power is transferred to the interaction term.



# Interactive activities



# Question 1

You are working on understanding the effect of Compound X on blood pressure in rats. To improve the generalizability of the study, you have decided to test a vehicle control vs Compound X in 3 different inbred strains of rat. You are not interested in whether the effect of Compound X differs across strains.

Which analysis strategy would you select for this design?

1. Pooling the data for an intervention and then running a t-test between treated and control data.
2. Disaggregating the data and completing separate t-tests between treated and control data for each strain.
3. A two-way ANOVA testing for main effects only.
4. A two-way ANOVA testing for main effects and an interaction.



## Question 2

You are working on understanding the effect of Compound X on blood pressure in rats. Based on the literature, you suspect that the drug may have a greater effect in females. You have decided to test vehicle control vs Compound X in both male and female rats.

Which analysis strategy would you select for this design?


1. Pooling the data for an intervention and then running a t-test between treated and control data.
2. Disaggregating the data and completing two separate t-tests between treated and control data.
3. A two-way ANOVA testing for main effects only.
4. A two-way ANOVA testing for main effects and an interaction.





# Question 3

You have run an experiment in both male and female mice, testing the effect of a drug designed to improve cardiac disease. You have obtained the following results.




1. From these data, predict the results obtained from each term of a two-way ANOVA (sex, treatment, interaction).
2. What is the biological conclusion?



## Question 4

4. You have run an experiment in both male and female mice, testing the effect of a drug designed to improve cardiac disease. You have obtained the following results.




1. From these data, predict the results obtained from each term of a two-way ANOVA (sex, treatment, interaction).
2. What is the biological conclusion?



## Question 5

You are testing the effect of knocking out a certain gene on a marker of inflammation in male and female mice. You have obtained the following results. The interaction term between sex and genetic status is statistically significant.



1. From these data, predict the results obtained from each term of a two-way ANOVA (sex, treatment, interaction).
2. What is the biological conclusion?



## Question 6:

Scenario: We have run an experiment where there is a baseline sex difference and the intervention increases the outcome variable. Which statistical method will be more sensitive to detect the intervention effect?

1. Pooling the data: A single t-test between treated and control.
2. Disaggregating the data by sex and a separate t-test between treated and control
3. A two-way ANOVA testing for main effects and an interaction.



# 6



REVIEW ARTICLE | [Free Access](#)

## Sex bias in preclinical research and an exploration of how to change the status quo

Natasha A Karp Neil Reavey

First published: 12 November 2018 | <https://doi.org/10.1111/bph.14539> | Citations: 20

This article is part of a themed section on The Importance of Sex Differences in Pharmacology Research. To view the other articles in this section visit <http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.21/issuetoc>


# Exploring the barriers

**MISCONCEPTIONS**

**SKILL GAP**


**PRACTICAL CONCERNS**

**3R INTERPRETATION OF REDUCTION**



# Misconception: hormonal cycles: females more variable

## Rats Becker 2016 BSD



“Female rats were not more variable at any stage of the estrous cycle than male rats.”

## Mice Prendergast 2014 NNBR

- meta-analysis 293 published articles
- behavioral, physiological, morphological, and molecular traits
- CV distribution = no differences
- At trait level – for three types of traits males were more variable than females

“Randomly cycling female mice were no more variable than males on any trait.”



# Inclusion isn't at odds with the 3R mindset

1. Breeding – produces both males and female animals
2. Reduction in N across experiments – more efficient to include both sexes

	Standard	Contemporary
Reduction	Methods which minimise the number of animals used per experiment	Appropriately designed and analysed animal experiments that are robust and reproducible, and truly add to the knowledge base



# Fear of change

“To date, sex hasn’t explained variation in my model”

- Lack of data regarding sex differences does not indicate there are none
- The goal isn’t to identify sex differences but to estimate generalisable effects and be able to detect very large differences when they do occur
- Meta analysis has found that data analysis is often poorly conducted and hence historic conclusions can be misleading [<https://elifesciences.org/articles/70817>]

“My prior work has only considered in one sex”

- Unfortunately it carries lots of risk.
- “ To change is difficult. Not to change is fatal” William Pollard



My research to date has only studied one sex.

Why not both?

To include both would require the sample size to be doubled and that isn't ethical.

Research has shown that you can use a factorial design and you just share your N across both sexes and estimate the treatment effect from both

I can't do that because the effect would be different in the two sexes


Provided it is in the same direction, the factorial design would estimate the average effect and account for any baseline difference

No the effect is too different – I have to have an individual estimate. We also just don't know and it would be risky to assume it will be the same

But when you are studying one sex you are assuming it is the same. Is this the fear of the unknown and change in how we work? Opposite direction is biologically rare. Following the sex inclusive design would actually allow us to know when there is a big difference .



# Single sex justification



The justification could be appropriate following exploration for that study of logistical, ethical, or cost implications relative to the benefit of using both sexes of animals in a research proposal.



# SIRF: Sex Inclusive Research Framework


## Why?

- Regulatory bodies assessing whether a research proposal is appropriate
- Frequently barriers are misconceptions
- Need transparency in the decision-making process
- We need educational resource to help move into considered justification to assess whether sex inclusion is a possibility.

## What?

- Decision tree of ten questions and associated supporting information
- Delivers 1 or more classifications
- Options:
  - **Green**: Proposal is appropriate
  - **Amber**: Caution is required (i.e., the proposed design/analysis carries some risk)
  - **Red**: Justification for single sex study in the proposal is not sufficient





# Activity

- Use the framework to evaluate some published justifications for the design implemented [<https://elifesciences.org/articles/56344>]
- Determine whether the research was
  - **Green** – design was appropriate from a sex inclusive research perspective
  - **Amber** – research study raises some caution statements due to risk in the design/analysis
  - **Red** – design was not appropriate from a sex inclusive research perspective



# Slido voting!

- Participants can vote at [Slido.com](https://slido.com) with #7809431





## Justification 1: we pooled the data because .....

"We could not compare the sexes as only four of the 25 wood mice were females. However, we have previously shown that the sex of wood mice has no effects on seed management "

Assessment options:

- **Green** – design was appropriate from a sex inclusive research perspective
- **Amber** – research study raises some caution statements due to risk in the design/analysis
- **Red** – design was not appropriate from a sex inclusive research perspective



## Justification 2: sex was not considered because .....

"All animals analysed were P3 or younger, thus no sex determination was attempted. Analyses are thought to include animals of both sexes at approximately equal proportions."

Assessment options:

- **Green** – design was appropriate from a sex inclusive research perspective
- **Amber** – research study raises some caution statements due to risk in the design/analysis
- **Red** – design was not appropriate from a sex inclusive research perspective



## Justification 3: single sex design because .....

"Because collecting vaginal smears to control oestrous cycle in females would add an extra layer of stress to our experiments, we performed the experiments in male pups only. "

Assessment options:

- **Green** – design was appropriate from a sex inclusive research perspective
- **Amber** – research study raises some caution statements due to risk in the design/analysis
- **Red** – design was not appropriate from a sex inclusive research perspective



## Justification 4: single sex design because .....

"We chose to use male mice, as female mice tend to have twice the levels of circulating CORT as males, and these levels may shift in response to stage of the oestrus cycle "

Assessment options:

- **Green** – design was appropriate from a sex inclusive research perspective
- **Amber** – research study raises some caution statements due to risk in the design/analysis
- **Red** – design was not appropriate from a sex inclusive research perspective



## Justification 5: Some studies had a single sex design because .....

"[we only used male mice as Foxp3Sf is X-linked]. The transfer experiments were with male mice as the Foxp3Sf Th9 cells were obtained from male mice and could not be transferred to females due to risk of rejection"


Assessment options:

- **Green** – design was appropriate from a sex inclusive research perspective
- **Amber** – research study raises some caution statements due to risk in the design/analysis
- **Red** – design was not appropriate from a sex inclusive research perspective



7

# Conclusions



# Conclusions

- Research suggests that sex is a significant source of variation for both *in vivo* and *in vitro*.
- Improving translation requires us to embrace variation. Sex is binary and is an easy first step to improve generalisability.
- However, sex bias is culturally embedded in our research pipelines, impacting the reporting, design, and analysis.
- Many of the barriers are misconceptions.
- Including both sexes, is not at odds with a reduction mindset.
- The expectations is changing. We need to work out how to consider sex mindfully and effectively.



# Acknowledgements



Neil Reavey  
Natasha Karp  
Ben Phillips  
Timo Haschler

## Decision Tree development:

Manuel Berdoy – University of Oxford  
Lillian Hunt – Wellcome Trust  
Maggy Jennings – RSPCA  
Angela Kerton the Learning Curve Ltd  
Matt Leach – Newcastle University  
Jordi Lopez-Tremoleda - Queen Mary Uni of London  
Jon Gledhill – Newcastle University  
Esther J. Pearl – NC3Rs  
Nathalie Percie du Sert – NC3Rs  
Penny Reynolds – University of Florida  
Kathy Ryder – Department of Health, Northern Ireland  
Clare Stanford – UCL  
Sara Wells – MRC Harwell  
Lucy Whitfield – OWL Vets Ltd


## Prevalence of sexual dimorphism



Richard Mott  
Judith Mank



Ruth Heller  
Shay Yaccoby  
Yoav Benjamini



Jeremy Mason

## Confidentiality Notice

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203 749 5000, [www.astrazeneca.com](http://www.astrazeneca.com)

